UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Madrigal Pharmaceuticals
MDGL
$11.9B
| $3.75M | ﹤0.01% |
+15,472
| New | +$4.22M |
|
1302
Navient
NAVI
$805M
| $3.75M | ﹤0.01% |
234,333
+19,524
| +9% | +$341K |
|
1303
ABM Industries
ABM
$2.82B
| $3.74M | ﹤0.01% |
83,170
+4,157
| +5% | +$192K |
|
1304
Tandem Diabetes Care
TNDM
$1.58B
| $3.73M | ﹤0.01% |
91,953
+3,585
| +4% | +$148K |
|
1305
ChargePoint
CHPT
$157M
| $3.72M | ﹤0.01% |
17,776
-1,193
| -6% | -$260K |
|
1306
CRISPR Therapeutics
CRSP
$5.18B
| $3.72M | ﹤0.01% |
82,286
+6,380
| +8% | +$310K |
|
1307
Atlantic Union Bankshares
AUB
$5.92B
| $3.72M | ﹤0.01% |
106,134
+5,149
| +5% | +$190K |
|
1308
Duolingo
DUOL
$6.28B
| $3.72M | ﹤0.01% |
26,056
-20,214
| -44% | -$2.08M |
|
1309
Grocery Outlet
GO
$971M
| $3.7M | ﹤0.01% |
130,767
+224
| +0.2% | +$6.43K |
|
1310
Hancock Whitney
HWC
$6.22B
| $3.69M | ﹤0.01% |
101,291
-1,686
| -2% | -$78.7K |
|
1311
Arcosa
ACA
$7.11B
| $3.69M | ﹤0.01% |
58,412
+7,605
| +15% | +$446K |
|
1312
Rhythm Pharmaceuticals
RYTM
$7.92B
| $3.68M | ﹤0.01% |
206,035
+163,838
| +388% | +$4.11M |
|
1313
Genworth Financial
GNW
$3.72B
| $3.66M | ﹤0.01% |
729,318
+22,416
| +3% | +$124K |
|
1314
Champion Homes
SKY
$5.06B
| $3.66M | ﹤0.01% |
48,650
-5,624
| -10% | -$363K |
|
1315
PennyMac Financial
PFSI
$3.9B
| $3.65M | ﹤0.01% |
61,273
+2,526
| +4% | +$156K |
|
1316
AMC Entertainment Holdings
AMC
$2.18B
| $3.62M | ﹤0.01% |
72,275
-14,326
| -17% | -$759K |
|
1317
Innospec
IOSP
$2.28B
| $3.62M | ﹤0.01% |
35,251
+1,678
| +5% | +$181K |
|
1318
Kirby Corp
KEX
$7B
| $3.59M | ﹤0.01% |
51,441
-2,213
| -4% | -$152K |
|
1319
Vishay Intertechnology
VSH
$5.17B
| $3.58M | ﹤0.01% |
158,362
+16,226
| +11% | +$357K |
|
|
UCB
1320
United Community Banks
UCB
$4.25B
| $3.58M | ﹤0.01% |
127,341
+7,299
| +6% | +$231K |
|
1321
Castle Biosciences
CSTL
$1B
| $3.57M | ﹤0.01% |
157,322
-1,741
| -1% | -$42.5K |
|
1322
PTC Therapeutics
PTCT
$6.16B
| $3.56M | ﹤0.01% |
73,490
+5,621
| +8% | +$257K |
|
|
AMED
1323
DELISTED
Amedisys
AMED
| $3.52M | ﹤0.01% |
+47,904
| New | +$4.14M |
|
1324
Array Technologies
ARRY
$822M
| $3.5M | ﹤0.01% |
159,839
+15,626
| +11% | +$320K |
|
|
TPH
1325
DELISTED
Tri Pointe Homes
TPH
| $3.5M | ﹤0.01% |
138,056
-13,098
| -9% | -$297K |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.